Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
June 1, 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
May 30, 2026
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 30, 2026
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 29, 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 29, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 29, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
May 24, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
May 18, 2026
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
January 21, 2026